tldrdailynews.com logo

China Emerges as a Key Player in Weight Loss Drug Development

1 min read
Source: Medscape
China Emerges as a Key Player in Weight Loss Drug Development
Photo: Medscape
TL;DR

Ecnoglutide, a new GLP-1 receptor agonist, demonstrated significant weight loss and improved cardiometabolic risk factors in a phase 3 trial involving overweight and obese adults, showing promise as a personalized obesity therapy with potential advantages over existing treatments.

Topics:businesshealth-and-medicine#ecnoglutide#glp-1-receptor-agonist#health-and-medicine#metabolic-benefits#obesity-treatment#weight-loss
Share this article
  1. Novel GLP-1 Agonist Promotes Safe and Effective Weight Loss  Medscape
  2. China's Sciwind's GLP-1 shows similar weight loss to Novo's Wegovy, study finds  Reuters
  3. Chinese Biotech Showcases Challenger to Eli Lilly’s Obesity Drug  Bloomberg.com
  4. SLIMMER: Ecnoglutide Demonstrates Weight Loss Potential in Phase 3 Trial  HCPLive
  5. China, where obesity levels are low, becomes hotbed for weight loss drug trials  STAT

Want the full story? Read the original reporting

Read on Medscape